Outcome of treatment for Helicobacter pylori infection in the Carinthian region;Uspešnost zdravljenja okužbe z bakterijo Helicobacter pylori v koroški regiji

Zdravniski Vestnik

Volumn 83, Issue 1, 2014, Pages 36-44

  Vujasinović, Miroslav ^a   Jeverica, Samo ^b   Robač, Nace ^a   Dolinar, Urša ^b   Tepeš, Bojan ^c  

^a Splošna bolnišnica Slovenj Gradec ^*  (Slovenia)

^b In titut za mikrobiologijo in parazitologijo   (Slovenia)

^c Abakus Medico doo Diagnosti ni center Roga ka   (Slovenia)

Author keywords

Antimicrobial resistance; Antimicrobial therapy; Eradication rate; Helicobacter pylori

Indexed keywords

EID: 84893643262     PISSN: 13180347     EISSN: 15810224     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Cave DR. Transmission and epidemiology of Helicobacter pylori. Am J Med 1996; 100 (5A): 12-8.
2. Pounder RE, Ng D. The prevalence of Helicobacter pylori in different countries. Aliment Pharamacol Ther 1995; 9 Suppl 2: 33-9.
3. Crowe SE, Feldman M, Grover S. Association between Helicobacter pylori infection and duodenal ulcer. UpToDate, version 19.3, elektronski medmrežni dostop 9.2.2012.
4. Jensen PJ, Feldman M, LaMont JT, Grover S. Acute and chronic gastritis due to Helicobacter pylori. UpToDate, version 19.3, elektronski medmrežni dostop 9.2.2012.
5. DuBois S, Kearney D. Iron-deficiency anemia and Helicobacter pylori infection. A review of evidence. Am J Gastroenterol 2005; 100: 453-9.
6. Franchini M, Cruciani MM, Mengoli CC. Effect of Helicobacter pylori eradication on platelet count in idiopatic trombocitopenic purpura: a systematic review and meta analysis. J Antimicrob Chemoter 2007; 60: 237-46.
7. Hernando-Harder AC, Booken N, Goerdt S, Singer MV, Hender H. Helicobacter pylori infection and dermatologic diseases. Eur J Dermatol 2009; 19: 431-44.
8. European Helicobacter Study Group. Current European concepts in the menagement of Helicobacter pylori infection. The Maastricht consensus Report. Gut 1997; 41: 8-13.
9. Malfertheiner P, Megraud F, O'Morain C, Hungin APS, Jones R, Axon A et al. Current concepts in the menagement of Helicobacter pylori infectionThe Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 167-80.
10. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D etal. Current concepts in the menagement of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56: 772-81.
11. Malfertheiner P, Megraud F, O'Morain C, Atherton J, Axon ATR, Bazzoli F et al. Management of Helicobacter pylori infection: the Maastricht IV/ Florence Consensus Report. Gut 2012; 61: 646-64.
12. Tepeš B, Križman I. Priporočila za zdravljenje okužbe z bakterijo Helicobacter pylori v Sloveniji. Zdrav Vestn 1998; 67: 159-62.
13. Tepeš B, Štabuc B. Priporočila Slovenskega združenja za gastroenterologijo in hepatologijo za zdravljenje okužbe z bakterijo Helicobacter pylori. Zdrav Vestn 2011; 80: 647-56.
14. Gubina M, Tepeš B, Vidmar G, Ihan A, Logar J, Wraber-Herzog B et al. Prevalenca protiteles proti bakteriji Helicobacter pylori v Sloveniji v letu 2005. Zdrav Vestn 2006; 75: 169-73.
15. Tepeš B, Ojsteršek Z. Uspešnost zdravljenja okužbe z bakterijo Helicobacter pylori v Sloveniji v letu 2008. Zdrav Vestn 2010; 79: 19-24.
16. Jeverica S, Tepeš B, Ihan A, Skvarč M. Primarna odpornost bakterije Helicobacter pylori. Zdrav Vestn 2010; 79: 25-30.
17. Megraud F, Lehours P. Helicobacter pylori Detection and Antimicrobial Susceptibility Testing. Clin Microbiol Rev 2007; 20: 280-322.
18. Rak v Sloveniji 2009. Ljubljana: Onkološki inštitut Ljubljana, Epidemiologija in register raka, Register raka Republike Slovenije, 2013.
19. Graham DY, Shiotani A. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol 2008; 5: 321-31.
20. Breuer T, Graham DY. Costs of diagnosis and treatment of Helicobacter pylori infection: when does choosing the treatment regimen based on susceptibility testing become cost effective? Am J Gastroenterology 1999; 94: 725-9.
21. Gerrits MM, Schuijffel D, van Zwet AA, Kuipers EJ, Vandenbroucke-Grauls CMJE, Kusters JG. Alterations in penicillin-binding protein 1A confer resistance to beta-lactam antibiotics in Helicobacter pylori. Antimicrob Agents Chemother 2002; 46: 2229-33.
22. Graham DY, Dore MP. Helicobacter pylori therapy demystified. Helicobacter 2011; 16: 343-5.
23. Calvet X, Gisbert JP, Suarez D. Key points for designing and reporting Helicobacter pylori therapeutic trials: a personal view. Helicobacter 2011; 16: 346-55.
24. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Infection with Helicobacter pylori. In: Schistosomes, Liver Flukes and Helicobacter pylori. Lyon; IARC Monographs 2009: 177-240.
25. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991; 325: 1127-31.
26. Wang C, Yuan Y, Hunt RH. The association between Helicobacter pylori infection and early gastric cancer: a meta-analysis. Am J Gastroenterol 2007; 102: 1789-98.
27. Brenner H, Arndt V, Stegmaier C, Ziegler H, Rothenbacher D. Is Helicobacter pylori infection a necessary condition for noncardia gastric cancer? Am J Epidemiol 2004; 159: 252-8.
28. Talley NJ, Fock KM, Moayyedi P. Gastric cancer consensus conference recommends Helicobacter pylori screening and treatment in asymptomatic persons from high risk populations to prevent gastric cancer. Am J Gastroenterol 2008; 103: 510-4.
29. Mabe K, Ohno M, Ishigaki S, Suzuki M, Takahashi M, Ono S et al. Multi-center study of gastric cancers detected after Helicobacter pylori eradication. Abstract No. P5.09, Helicobacter 2012; 17 Suppl 1: 112.
30. Graham DY, Shiotani, A. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol 2008; 5: 321-31.
31. Giorgio F, Principi M, de Francesco V, Zullo A, Losurdo G, Di Leo A, et al. Primary clarithromycin resistance to Helicobacter pylori: Is this the main reason for triple therapy failure? World J Gastrointest Pathophysiol 2013; 4: 43-6.
32. Zullo, A., Vaira, D., Vakil, N., Hassan, C., Gatta, L., Ricci, C., et al. High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment Pharmacol Ther 2003; 17: 719-26.
33. Gatta L, Vakil N, Vaira D, Scarpignato C. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ 2013; 347: 1-14.
34. McNicholl AG, Marin AC, Molina-Infante J, Castro M, Barrio J, Ducons J, et al. Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice. Gut 2013; (published online first on May 11, doi: 10.1136/gutjnl-2013-304820).
35. Huang Y-K, Wu M-C, Wang SS, Kuo C-H, Lee Y-C, Chang L-L, et al. Lansoprazole-based sequential and concomitant therapy for the first-line Helicobacter pylori eradication. J Dig Dis 2012; 13: 232-8.
36. Georgopoulos S, Papastergiou V, Xirouchakis E, Laoudi F, Lisgos P, Spiliadi C, et al. Nonbismuth quadruple "concomitant" therapy versus standard triple therapy, both of the duration of 10 days, for first-line H. pylori eradication: a randomized trial. J Clin Gastroenterol 2013; 47: 228-32.
37. Cosme A, Montes M, Martos M, Gil I, Mendarte U, Salicio Y, et al. Usefulness of antimicrobial susceptibility in the eradication of Helicobacter pylori. Clin Microbiol Infect 2013; 19: 379-83.